These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38979086)

  • 1. Rituximab-induced serum sickness in immunobullous disorders: A case series.
    Gheisari M; Safari Giv T; Pourgholi E; Zaresharifi S
    Clin Case Rep; 2024 Jul; 12(7):e9152. PubMed ID: 38979086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab-induced serum sickness in a girl with nephrotic syndrome.
    Kimura Y; Kiyota K; Ikeuchi M; Sekiguchi K; Ihara K
    CEN Case Rep; 2022 Nov; 11(4):506-510. PubMed ID: 35596114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome.
    Nakamura M; Kanda S; Yoshioka Y; Takahashi C; Owada K; Kajiho Y; Harita Y; Oka A
    CEN Case Rep; 2020 May; 9(2):173-176. PubMed ID: 31970629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration.
    Mahmoudi H; Tavakolpour S; Balighi K; Farid AS; Nili A; Jan D; Daneshpazhooh M
    Dermatol Ther; 2021 Jan; 34(1):e14633. PubMed ID: 33280226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study.
    Bayer G; Agier MS; Lioger B; Lepelley M; Zenut M; Lanoue MC; Maillot F; Jonville-Bera AP
    Eur J Intern Med; 2019 Sep; 67():59-64. PubMed ID: 31279430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
    Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
    Front Immunol; 2022; 13():915205. PubMed ID: 35844526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum sickness with refractory nephrotic syndrome following treatment with rituximab.
    Maeda R; Kawasaki Y; Ohara S; Suyama K; Hosoya M
    CEN Case Rep; 2018 May; 7(1):69-72. PubMed ID: 29305810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The case of Kawasaki disease after rituximab infusion triggered by human anti-chimeric antibodies.
    Sato M; Yamada M; Nakajima M; Miyama Y; Kitayama H
    CEN Case Rep; 2020 Nov; 9(4):392-394. PubMed ID: 32535844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases.
    Mahmoudi H; Balighi K; Tavakolpour S; Daneshpazhooh M
    Int Immunopharmacol; 2019 Jun; 71():40-42. PubMed ID: 30877872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab-Induced Serum Sickness Overlapping With Anaphylaxis: A Case Report.
    Cottu A; Chaara T; Caré W; Vanquaethem H; Nielly H
    Cureus; 2023 Apr; 15(4):e38333. PubMed ID: 37266062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
    Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
    Front Immunol; 2018; 9():248. PubMed ID: 29520266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of the long-term therapeutic effectiveness and safety profile of rituximab in the treatment of mucous membrane pemphigoid in a German university center between 2008 and 2019.
    Bamberger F; König IR; Gola D; Zillikens D; Sadik CD
    Front Immunol; 2023; 14():1180150. PubMed ID: 37143653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of rituximab in the treatment of mucous membrane pemphigoid: An analytic review.
    Farooq MM; Miloslavsky EM; Konikov N; Ahmed AR
    Autoimmun Rev; 2022 Aug; 21(8):103119. PubMed ID: 35688385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients.
    Kianfar N; Dasdar S; Mahmoudi H; Tavakolpour S; Balighi K; Daneshpazhooh M
    J Dermatolog Treat; 2022 Mar; 33(2):869-874. PubMed ID: 32589481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab-induced serum sickness: A systematic review.
    Karmacharya P; Poudel DR; Pathak R; Donato AA; Ghimire S; Giri S; Aryal MR; Bingham CO
    Semin Arthritis Rheum; 2015 Dec; 45(3):334-40. PubMed ID: 26199061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in Mucous Membrane Pemphigoid: A Monocentric Retrospective Study in 10 Patients with Severe/Refractory Disease.
    Baffa ME; Corrà A; Maglie R; Mariotti EB; Montefusco F; Pipitò C; Senatore S; Quintarelli L; Caproni M; Antiga E
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-induced serum sickness and anaphylaxis in a child with nephrotic syndrome.
    Bayram MT; Soylu A; Kavukçu S
    Turk J Pediatr; 2020; 62(5):884-888. PubMed ID: 33108096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
    Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
    Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
    Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
    J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
    [No Abstract]   [Full Text] [Related]  

  • 20. The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary evaluation.
    Arduino PG; Broccoletti R; Carbone M; Conrotto D; Sciannameo V; Gambino A; Cabras M; Carrozzo M; Baldovino S
    J Oral Pathol Med; 2020 Feb; 49(2):177-180. PubMed ID: 31804741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.